Solventum Corporation (SOLV) stock score and earnings-call analysis

What the SOLV earnings call showed (fiscal 2026 Q3)

Solventum delivered Q3 FY2026 results with reported sales down 7% YoY but normalized organic growth of ~4% driven by volume. Gross margin expanded 120 bps to 57.1%; operating margin declined 70 bps to 19.9% due to ERP reversal, but normalized operating margin was ~22.3%. Management raised FY2026 guidance to the high end across organic sales (2.5-3%, ~4% ex-SKU), operating margin (22.2-22.7%), and EPS ($7.20-7.30). Separation from 3M is >90% complete with supply agreement renegotiation eliminating a 100 bps gross margin headwind from 2027. HIS separation announced with ~400 bps near-term margin dilution but proceeds to fund debt paydown and shareholder returns. Growth drivers show strong traction with significant underpenetration (V.A.C. at ~10% penetration). Transform for the Future savings at $160M of $500M target. Underlying FCF ~$1B ex-separation costs. 2028 LRP target 23-25% operating margin confidence increased.

Operating signals

• Revenue: Mixed. Reported sales fell 7% YoY due to divestitures and ERP order reversal, but normalized organic growth was ~4% driven by volume. Key figures: Reported sales: $1.95 billion (down 7% YoY); Organic sales growth: -2.8% (includes $125M ERP reversal (630 bps headwind)); Normalized organic growth: ~4% (excludes ERP timing and SKU rationalization).
• Margins: Up. Gross margin expanded 120 bps YoY to 57.1%; operating margin declined 70 bps YoY to 19.9% due to ERP reversal, but normalized operating margin was ~22.3% ahead of expectations. Key figures: Gross margin: 57.1% (up 120 bps YoY); Operating margin: 19.9% (down 70 bps YoY); Transform for the Future savings: $160 million (of $500 million annual target).
• Guidance: Likely increase. Raised FY2026 organic sales guidance to high end of 2.5-3% range (~4% ex-SKU), raised operating margin to high end of 22.2-22.7%, and increased EPS to $7.20-7.30 from $7.10-7.20, with confidence in 2027 margin expansion despite tariff headwind. Key figures: FY2026 organic sales guidance: High end of 2.5-3% (~4% ex-SKU) (YTD normalized ~4%); FY2026 operating margin guidance: High end of 22.2-22.7% (Initial outlook 21-21.5%); FY2026 EPS guidance: $7.20-7.30 (Raised from $7.10-7.20).
• Demand: Up. Underlying demand strong with ~4% normalized organic growth driven by volume; growth drivers (V.A.C. therapy, IV site management, sterilization assurance, core restoratives, revenue cycle management) showing traction with significant underpenetration opportunity. Key figures: Normalized organic growth: ~4% (Volume primary driver); V.A.C. therapy penetration: ~10% (Addressable: 10.5M Medicare beneficiaries); Acera growth: 35% (Best quarter on record).
• Forward outlook: Up. FY2026 guidance raised across organic sales (high end 2.5-3%), operating margin (high end 22.2-22.7%), and EPS ($7.20-7.30), all above prior guidance ranges. Key figures: FY2026 organic sales guidance: High end of 2.5-3% (Prior guide: 2.5-3%); FY2026 operating margin guidance: High end of 22.2-22.7% (Prior guide: 22.2-22.7%); FY2026 EPS guidance: $7.20-7.30 (Prior guide: $7.10-7.20).
• Risk: Medium. Key risks include tariff headwinds (120 bps margin impact in 2027), HIS separation execution (~400 bps near-term margin dilution), ERP cutover completion risk (largely mitigated), and integration execution; mitigated by supply agreement renegotiation, Transform for the Future savings, separation cost roll-off, and strong FCF generation. Key figures: Tariff margin impact: 120 bps headwind in 2027 (120 bps benefit in 2026 from refund); HIS separation margin dilution: ~400 bps operating margin (Near-term, before cost reductions); Transform for the Future savings: $160 million (Of $500 million annual target).
• Q&A directness: Mostly direct. Management answered most questions directly with numbers and timelines, though some strategic questions on HIS separation EPS impact were deferred due to process uncertainty.

Catalysts in play

• ERP cutover completed — 90%+ separation from 3M complete, removing major execution risk and freeing up FCF
• Raw material supply agreement with 3M renegotiated — eliminates 100bps gross margin headwind scheduled for April 2027, increases confidence in 2028 LRP target of 23-25% operating margin
• Growth drivers executing: V.A.C. Peel and Place (61% faster application), Acera integration ahead of plan (35% growth, 510(k) for combined use with V.A.C. received faster than expected), Dental new product launches (Clarity composite veneers 1,000+ smiles in limited launch)
• Guidance raised: organic sales growth toward high end of 2.5-3% (~4% ex-SKU), operating margin toward high end of 22.2-22.7%, EPS raised to $7.20-7.30 from $7.10-7.20
• HIS separation process advancing — proceeds to fund debt paydown and shareholder returns, RemainCo margin expansion levers concentrated in MedSurg/Dental

Risks in play

• HIS separation implies ~400bps near-term operating margin dilution (partially offset by TSA benefits and cost reductions), EPS dilution path unclear until separation method determined
• Tariff refund benefit (120bps in 2026) creates tough comp for 2027 — margin expansion must overcome this headwind
• Organic growth still reliant on penetration of existing technologies (V.A.C. only 10% penetrated) rather than market growth — execution risk on commercial strategy
• SKU rationalization headwind (90-100bps) continues into Q4 2026, then ends
• Free cash flow guidance maintained at $200-300M (majority in Q4) — heavily dependent on separation cost wind-down timing

Read from the earnings call transcript and the company's reported figures by MarketKingdoms' analysis.

SOLV management track record (fiscal 2026 Q3)

Management record score: 70 (High). MarketKingdoms checks each commitment made on a call against what the company later reported.

Solventum's Q3 2026 transcript shows strong claim follow-through on separation execution, with >90% completion confirmed by both CEO and CFO. Twelve measurable claims were extracted, including separation milestones (TSA exits, manufacturing moves, DC reductions due 2027), 2028 LRP margin target of 23-25%, Clarity veneers full launch in early 2027, and full-year 2026 guidance raised toward high ends. The Transform for the Future program reported $180M spent and $160M savings against $500M targets. Q&A accountability was solid: 5 answers classified with 2 direct-with-numbers (margin expansion detail, 400 bps HIS dilution), 2 direct-without-numbers, and 2 partial (EPS dilution deferred). No later transcripts available; most claims remain not_due or still_open.

Commitments tracked: 1 achieved, 1 on track.

• Separation from 3M is more than 90% complete; structural and risky work is done (target >90%), due 2026 Q3: achieved
• Complete remaining transition service agreements by end of 2027 (target 100%), due 2027 Q4: not yet due
• Complete five remaining manufacturing line moves in 2027 (target 5), due 2027 Q4: not yet due
• Exit nine more distribution centers to reach target of 45 (target 45), due 2027 Q4: not yet due
• Whole-company 2028 long-range plan operating margin target of 23% to 25% (target 23% to 25%), due 2028 Q4: not yet due
• Full launch of Clarity composite veneers expected in first part of 2027 (target full_launch), due 2027 Q1: not yet due
• 2026 organic sales growth toward high end of 2.5% to 3% range (target 2.5% to 3%), due 2026 Q4: not yet due
• 2026 full-year gross margin approximately 57% (target 57%), due 2026 Q4: not yet due

Analyst questions answered: 2 partial.

How specific SOLV management was (fiscal 2026 Q3)

Specificity score: 96 (Very high): how much of the call is concrete figures, named drivers and dated plans rather than general language.

Solventum's Q3 2026 transcript demonstrates exceptionally high specificity across financial results, separation progress, portfolio actions, and guidance. Management quantified ERP reversal impacts ($125M, 630 bps), normalized growth (~4%), segment drivers, gross/operating margin bridges with bps attribution, separation milestones (90%+, plant/DC counts, TSA exits), supply agreement benefits (avoided 100 bps headwind April 2027), and raised 2026 guidance with precise ranges. Q&A was notably direct with numbers on guidance mechanics, margin trajectory, and HIS separation math. Filler phrases were minimal and mostly confined to opening/closing framing. Evidence traceability is strong with most claims combining metric, number, driver, segment, and timeline.

Q&A: 5 analyst questions, 3 answered directly with numbers. Management provided highly direct, numerically grounded answers on guidance mechanics, margin bridge into 2027, and HIS separation financial framework; only qualitative strategic questions received non-numeric but still direct responses.

Specificity factors (0–100): Low filler 82, Kpi anchoring 90, Qa directness 85, Risk specificity 78, Numerical density 85, Guidance precision 92, Operational detail 88, Timeline specificity 88, Evidence traceability 88, Named entity segment detail 92, Variance explanation quality 90.

Medical Instruments & Supplies peers

Near SOLV in the overall ranking

• 1. International Seaways Inc (INSW): 84.7 (A)
• 2. DHT Holdings Inc (DHT): 83.2 (A)
• 3. Micron Technology Inc. (MU): 82.8 (A)

How MarketKingdoms scores companies

The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.

General information, not investment advice.